Sugi Predict

Sugi Predict / Compounds / SCHEMBL2472987

SCHEMBL2472987

SCHEMBL2472987

COC(=O)/C=C/c1ccc(C)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 2/20 0.72
▸ CA1 P00915 2/20 0.72
▸ CA2 P00918 2/20 0.72
▸ CA7 P43166 2/20 0.72
▸ CA9 Q16790 2/20 0.72
▸ CA14 Q9ULX7 2/20 0.72
▸ TYR P14679 1/20 0.72
▸ PTPN1 P18031 1/20 0.62
▸ TTR P02766 1/20 0.61
▸ APP P05067 1/20 0.61
▸ MAPT P10636 6/20 0.58
▸ ALOX5 P09917 1/20 0.57
▸ MAOA P21397 2/20 0.56
▸ MAOB P27338 2/20 0.56
▸ EPHX2 P34913 1/20 0.56
▸ SMN1; SMN2 Q16637 3/20 0.55
▸ TP53 P04637 1/20 0.55
▸ THRB P10828 1/20 0.55
▸ FOS P01100 1/20 0.55
▸ JUN P05412 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19397275 1.00 CA12 (0.72) CA12CA1CA2CA7CA9
SCHEMBL504081 1.00 CA12 (0.72) CA12CA1CA2CA7CA9
SCHEMBL10743297 0.98 CA12 (0.70) CA12CA1CA2CA7CA9
SCHEMBL5057418 0.92 CA12 (0.84) CA12CA1CA2CA7CA9
SCHEMBL71224 0.92 CA12 (0.84) CA12CA1CA2CA7CA9
SCHEMBL16201623 0.87 MAPT (0.76) CA12CA1CA2CA7CA9
SCHEMBL28061671 0.85 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL27617009 0.85 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL1192079 0.85 MAPT (0.55) CA12CA1CA2CA7CA9
Methyl P-Hydroxycinnamate SCHEMBL547438 0.84 CA12 (1.00) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 — — US claimed
CN-115594686-B Millpulin A derivative, preparation method and medical application thereof 沈阳药科大学 2023-10-13 — — CN claimed
CN-115594686-A Millpuline A derivatives, and preparation method and medical application thereof 沈阳药科大学（CN） 2023-01-13 — — CN claimed
CN-109796338-B Synthetic method of ozagrel intermediate p-bromomethyl cinnamate 深圳市第二人民医院 2022-05-06 — — CN claimed
CN-115959962-B Visible light-promoted halogenated alkane hydrodehalogenation method 中国科学院兰州化学物理研究所 2025-05-23 — — CN disclosed
US-20250075147-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NEW FLAVOR AND FRAGRANCE INGREDIENTS OSMO LABS, PBC 2025-03-06 — — US disclosed
CN-115141098-B Method for preparing ozagrel intermediate through microchannel reaction 赤峰经方医药技术开发有限责任公司 2024-10-15 — — CN disclosed
US-11833203-B2 Synthetic retinoids (in cell modulation) UNIVERSITY OF DURHAM 2023-12-05 — — US disclosed
CN-115594686-B Millpulin A derivative, preparation method and medical application thereof 沈阳药科大学 2023-10-13 — — CN disclosed
US-11655226-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2023-05-23 — — US disclosed
CN-115959962-A Visible light promoted halogenated alkane hydrodehalogenation method 中国科学院兰州化学物理研究所 2023-04-14 — — CN disclosed
CN-115594686-A Millpuline A derivatives, and preparation method and medical application thereof 沈阳药科大学（CN） 2023-01-13 — — CN disclosed
US-4584313-A TREATING SENILITY WARNER-LAMBERT COMPANY (US) 1986-04-22 — — US disclosed
EP-0164853-A1 (substituted-phenyl)-5-oxo-2-pyrrolidinepropanoic acids, a process for producing the compounds and pharmaceutical compositions comprising the compounds WARNER-LAMBERT COMPANY (US) 1985-12-18 — — EP disclosed
EP-0164852-A1 1-(Substituted-aryl)-Dihydro-1H-pyrrolizine-3,5-(2H,6H-)diones, a process for producing the compounds and a pharmaceutical composition comprising the compounds WARNER-LAMBERT COMPANY (US) 1985-12-18 — — EP disclosed
US-4548947-A 1-(Substituted-aryl)-dihydro-1H-pyrrolizine-3,5-[2H,6H-]diones and use for reversing amnesia WARNER-LAMBERT COMPANY (US) 1985-10-22 — — US disclosed
EP-0083228-B1 PHARMACEUTICALLY ACTIVE PHENYLCARBOXYLIC ACID DERIVATIVES ICI AMERICAS INC. (US) 1985-05-15 — — EP disclosed
US-4499299-A Pharmaceutically active phenylcarboxylic acid derivatives ICI AMERICAS INC. (US) 1985-02-12 — — US disclosed
EP-0083228-A1 Pharmaceutically active phenylcarboxylic acid derivatives ICI AMERICAS INC. (US) 1983-07-06 — — EP disclosed
US-4309443-A ANTI-OBESITY, HYPOGLYCEMIC BEECHAM GROUP LIMITED (GB) 1982-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11833203-B2 Synthetic retinoids (in cell modulation) RARA, RARB, RXRA CA12 3772/4885CA1 3436/4885CA2 4475/4885
US-11655226-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A CA12 4225/4885CA1 3493/4885CA2 3486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.